Mina, Fahmida Begum, Billah, Mutasim, Rahman, Md. Siddikur, Das, Sabuj, Karmakar, Sumon, Acharjee, Uzzal Kumar, and Hasan, Md. Faruk (2021) Convalescent plasma: Alternative or promising therapy? Journal of Global Antimicrobial Resistance, 24. pp. 246-248.

Preview

PDF (Published Version) - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (260kB) | Preview

Abstract

In the context of an infectious disease epidemic for which there is neither a cure nor a vaccine, such as the recent COVID-19 (coronavirus disease 2019) pandemic, treatment with convalescent plasma, in which health professionals transfer the antibody-rich blood plasma of recently recovered patients to those critically ill, can provide humoral immunity in the short to medium term by quickly strengthening a person’s passive immune system against a virus. The use of convalescent plasma dates back to the 1900s but has more recent precedents, which indicate its efficacy as a relatively effective stopgap measure against evolving viral infections. From H1N1 influenza to Ebola virus disease to the foremost predecessor of COVID-19, namely severe acute respiratory syndrome (SARS), medical practitioners have constantly switched to this specific type of passive immune therapy and documented encouraging decreases in mortality and viral load in many cases. Following the emergence of the COVID-19 pandemic, some researchers proposed convalescent plasma treatment as a possible therapeutic, as the use of plasma from patients several days or weeks after recovering from COVID-19 has the potential advantage of supplying appropriate virus-neutralising antibodies before structured therapies can be developed [1]. When a patient makes a complete recovery from COVID-19, immunoglobulin G (IgG) antibodies will maintain a memory of the disease for at least couple of months, ready to combat the infection.

Item ID:	93884
Item Type:	Article (Short Note)
ISSN:	2213-7173
Copyright Information:	© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This is an open access article under the CC BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Date Deposited:	02 Sep 2026 05:08
FoR Codes:	32 BIOMEDICAL AND CLINICAL SCIENCES > 3201 Cardiovascular medicine and haematology > 320102 Haematology @ 50% 32 BIOMEDICAL AND CLINICAL SCIENCES > 3207 Medical microbiology > 320705 Medical virology @ 30% 32 BIOMEDICAL AND CLINICAL SCIENCES > 3299 Other biomedical and clinical sciences > 329999 Other biomedical and clinical sciences not elsewhere classified @ 20%
SEO Codes:	20 HEALTH > 2001 Clinical health > 200105 Treatment of human diseases and conditions @ 100%
	More Statistics